Lipid Abnormalities in Type 2 Diabetes Mellitus Patients with Overt Nephropathy

다국어 초록 (Multilingual Abstract)

Background: Diabetic nephropathy is a major complication of diabetes and an established risk factor for cardiovascular events.
Lipid abnormalities occur in patients with diabetic nephropathy, which further increase their risk for cardiovascular events. We compared the degree of dyslipidemia among type 2 diabetes mellitus (T2DM) subjects with and without nephropathy and analyzed the factors associated with nephropathy among them.
Methods: In this retrospective study, T2DM patients with overt nephropathy were enrolled in the study group (n=89) and without nephropathy were enrolled in the control group (n=92). Both groups were matched for age and duration of diabetes. Data on total cholesterol (TC), triglycerides (TG), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), urea and creatinine were collected from the case sheets. TG/HDL-C ratio, a surrogate marker for small, dense, LDL particles (sdLDL) and estimated glomerular filtration rate (eGFR) were calculated using equations. Multivariate analysis was done to determine the factors associated with eGFR.
Results: Dyslipidemia was present among 56.52% of control subjects and 75.28% of nephropathy subjects (P=0.012). The percentage of subjects with atherogenic dyslipidemia (high TG+low HDL-C+sdLDL) was 14.13 among controls and 14.61 among nephropathy subjects. Though serum creatinine was not significantly different, mean eGFR value was significantly lower among nephropathy patients (P=0.002). Upon multivariate analysis, it was found that TC (P=0.007) and HDL-C (P=0.06) were associated with eGFR among our study subjects.
Conclusion: Our results show that dyslipidemia was highly prevalent among subjects with nephropathy. Regular screening for dyslipidemia may be beneficial in controlling the risk for adverse events among diabetic nephropathy patients.

참고문헌 (Reference)

1 Packard CJ, "Triacylglycerol-rich lipoproteins and the generation of small, dense low-density lipoprotein" 31 (31): 1066-1069, 2003

2 Keane WF, "The role of lipids in renal disease: future challenges" 75 : S27-31, 2000

3 Attman PO, "The compositional abnormalities of lipoproteins in diabetic renal failure" 13 : 2833-2841, 1998

4 Sandhu S, "Statins for improving renal outcomes: a meta-analysis" 17 : 2006-2016, 2006

5 Das BS, "Serum lipid in chronic renal failure" 32 : 1019-1021, 1984

6 Jisieike-Onuigbo NN, "Prevalence of dyslipidemia among adult diabetic patients with overt diabetic nephropathy in Anambra state south-east Nigeria" 14 : 171-175, 2011

7 Breyer JA, "Predictors of the progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathy. The Collaborative Study Group" 50 : 1651-1658, 1996

8 Parving HH, "Microalbuminuria: a parameter that has changed diabetes care" 107 : 1-8, 2015

9 Haffner SM, "Management of dyslipidemia in adults with diabetes" 26 (26): S83-S86, 2003

10 Contreras G, "Malnutrition-inflammation modifies the relationship of cholesterol with cardiovascular disease" 21 : 2131-2142, 2010

11 Jenkins AJ, "Lipoproteins in the DCCT/EDIC cohort: associations with diabetic nephropathy" 64 : 817-828, 2003

12 Samuelsson O, "Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency" 12 : 1908-1915, 1997

13 Trevisan R, "Lipids and renal disease" 17 (17): S145-147, 2006

14 Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group, "KDIGO clinical practice guideline for lipid management in chronic kidney disease" 3 : 259-305, 2011

15 UK Prospective Diabetes Study (UKPDS) Group, "Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)" 352 : 837-853, 1998

16 Krolewski AS, "Hypercholesterolemia:a determinant of renal function loss and deaths in IDDM patients with nephropathy" 45 : S125-131, 1994

17 Hirano T, "High prevalence of small LDL particles in non-insulin-dependent diabetic patients with nephropathy" 123 : 57-72, 1996

18 UK Prospective Diabetes Study Group, "Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39" 317 : 713-720, 1998

19 Go AS, "Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization" 351 : 1296-1305, 2004

20 Schaeffner ES, "Cholesterol and the risk of renal dysfunction in apparently healthy men" 14 : 2084-2091, 2003

21 Suchitra MM, "Atherogenic dyslipidemia in diabetic nephropathy:lipoprotein (a), lipid ratios and atherogenic index" 1 : 455-459, 2013

22 Wang F, "Association of high-density lipoprotein cholesterol with the estimated glomerular filtration rate in a community-based population" 8 : e79738-, 2013

23 Chen SC, "Association of cholesterol levels with mortality and cardiovascular events among patients with CKD and different amounts of proteinuria" 8 : 1915-1926, 2013

24 Chandy A, "Association between diabetic nephropathy and other diabetic microvascular and macrovascular complications" 19 : 924-928, 2008

25 Liu Y, "Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrit" 291 : 451-459, 2004

26 Appel GB, "Analysis of metabolic parameters as predictors of risk in the RENAAL study" 26 : 1402-1407, 2003

27 Sharma BK, "Absence of hyperlipidaemia in patients of chronic renal failure in Chandigarh" 72 : 461-464, 1980